Mirror, Mirror On the Wall: Which Recent College Graduates Have the Highest Unemployment Rates of All?
It is no secret that recent college graduates are having a tough time finding work. However, not all college majors are created equal and the unemployment rates among different disciplines are likely to vary. To answer this question, a group of researchers at the Georgetown Center on Education and Workforce analyzed employment data for recent college graduates from an in-depth US census study entitled the American Community Survey conducted in 2009 and 2010. In the study, recent college grades were defined as workers (with college degrees of course) between ages 22 and 26.
The results of the study are shown in the graph below.
The data clearly show that among recent college grads, those who studied architecture have the highest unemployment rate at 13.9%. This finding was not that surprisingly given that the collapse of the housing and construction markets were mainly responsible for the ongoing recession that began in 2007.
Unemployment rates were lowest among college graduates with training in education and healthcare. Again, these results are not that start. Again, these results were not startling because the US population continues to age (healthcare-related jobs) and the number of school-aged children skyrocketed in the past 20 years (education jobs).
Interestingly, the unemployment rate among engineering graduate, 7.4% is relatively high despite the fact that HR and employment experts contend that there is a shortage of engineers in the US.
Finally, unemployment rates among graduates with art degrees and those who possess degrees in the humanities and liberal art are still very high at 11.1% and 9.4% respectively. That said, maybe getting that MS or PhD degree in the life sciences was not such a bad idea after all!
Until next time...
Good Luck and Good Job Hunting!!!!!!!!!!!
Despite a stalling economy, there are signs that some American companies are hiring and helping to improve local economies. A good of example of this is Alcon Laboratories located in Fort Worth, Texas. The company, which specializes in vision products, (1).jpg)
While China and India have gotten the most attention as emerging pharmaceutical markets, Latin American markets most notably Mexico and Brazil (okay, it is a South American country but it can be included in Latin America) have been quietly expanding as rapidly as the Indian and Chinese markets. To wit, Denmark-based, Novo Nordisk—the world’s largest insulin maker—.jpg)
After completing the $6.8 billion purchase of Pennsylvania-based Cephalon, Teva, the world’s largest generic drug manufacturer
Despite the fact that women in the US earn nearly 60 percent of four-year college degrees and make up almost half of the American workforce, women held about 14 percent of senior executive positions at Fortune 500 companies. An even lower percentage of female scientists hold tenure track faculty positions. 
Astra Zeneca today announced that it will eliminate 400 positions at the company’s Wilmington, DE headquarters. Most of the cuts will be in sales and marketing and the downsizing is intended “streamline portions of its commercial business to best serve patients in the US.”
As scientists, we all subscribe to the notion that diversity is a critical component to the evolution of any species. While we this is a well known fact, the life sciences industry, like others, struggles with workforce diversity mainly in the area of research and development. For example the number of minority students—blacks and hispanics—who receive PhD degrees is miniscule as compared with their white counterparts. Graduate schools struggle to promote diversity in their programs but their efforts to date have been lackluster.
There is no longer any doubt that big pharma companies are beginning to 
Merck & Co, which yesterday completed its $430 million acquisition of Inspire Pharmaceuticals, 
Medtronic one of the world’s largest medical devices manufacturer earlier this week announced that it will 
.gif)
Most job pundits and career analysts believe that millions of jobs will become available in science, technology, engineering and math (STEM) by 2018. Yet, despite ongoing initiatives the next generation of American employees may be unprepared and not qualified to take advantage of these new opportunities. A recent .jpg)
The expanding European financial crisis is forcing drug makers to continue to explore ways in which to cut costs. Faced with budget deficits amid a global economic crisis, European countries such as Germany, France and Greece have cut or plan to cut their health-care spending. Greece last month ordered drugmakers, including France’s largest drug maker Sanofi-Aventis, to cut prices by 3 percent to 27 percent to help rescue its economy. .jpg)
For the past year or so, I have been focusing on the downsizing and layoffs taking place at big pharmaceutical companies. The unprecedented size and scope of these massive layoffs have overshadowed the downsizing and job loss taking place at small to mid-size public and private biopharmaceutical companies. In contrast with most fully-integrated vertical pharmaceutical companies that are flush with cash, most biotech companies—even the likes of Amgen, Genentech, Gilead and others—don’t have the cash reserves to maintain operations in a down economy or when a drug candidate fails in clinical development. This coupled with the lack of venture and private equity capital has been causing biopharmaceutical employees to lose sleep in recent months.
Ed Silverman, who runs the 
.jpg)
pharmaceutical industry and seemingly getting tougher.
According to an 
While ‘women in the workplace’ is no longer a new or novel concept, there are still differences in the way women and men are viewed and treated at work. Lauri Buckley at .jpg)
it would eliminate as many as 8,200 jobs, or 7% of its work force, to help the company cope with what it expects will be a slow economic recovery amid damped demand for drugs, medical devices and consumer products. J&J employs about 117, 000 workers globally. While the job cuts will be global, many losing their jobs will be outside of the US. 
According to a report yesterday, .jpg)
Over the past ten years or so, pundits have been warning that the US is losing its competitive edge and that it is no longer the world’s leading nation when it comes to innovation in science and technology. Measuring national competitiveness and innovation is very tricky business and until now, most of evidence to support these claims has been anecdotal. According to an 
.jpg)
On the heels of yesterday’s announcement that it wants to buy Genentech, Roche, in a surprise move, 
Siemens, the German conglomerate that manufactures everything from locomotives to medical imaging devices, officially announced on Tuesday that it will be sacking 4% of it workforce or 16,750 employees. Although the company didn’t specify where all of the cut would be taking place—it is a global workforce reduction—a company spokesperson did indicate that 1,500 administrative jobs in its healthcare division would be eliminated and most of those jobs are in the US. Many of these cuts will likely take place in the tri-state area (New York, New Jersey and Pennsylvania)—not welcome news for the already battered pharmaceutical and biotechnology industries in the region.
Cambridge, MA-based 
